文献速递乳腺癌

英国Sloane项目:9938例筛查检出导管原位癌的管理与5年结局

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.
PubMed 文献 · Eur J Cancer · 2018-08-06

该前瞻性队列纳入英国NHS乳腺筛查计划中筛查检出的9938例导管原位癌女性,分析治疗模式、复发与死亡。中位随访64个月,保乳术后加放疗与同侧复发绝对降低相关,内分泌治疗与任何同侧复发减少相关,但两者均未与5年内乳腺癌死亡率改善相关。

要点

  • 筛查检出DCIS经保乳或全乳切除后复发不常见,中位64个月随访6.8%出现进一步DCIS或浸润癌。
  • 保乳术后放疗与同侧DCIS/浸润癌复发绝对降低3.1%、同侧浸润癌复发绝对降低1.9%相关。
  • 辅助内分泌治疗与保乳术后任何同侧复发减少相关,不论是否接受放疗。

核心结论

  • 筛查检出DCIS治疗后复发DCIS或浸润癌不常见,放疗和内分泌治疗与进一步事件减少相关,但5年内未显示乳腺癌死亡率获益。

研究设计与样本

  • 前瞻性队列研究,纳入2003年4月1日至2012年3月31日英国NHS乳腺筛查计划筛查检出的9938例DCIS女性,平均年龄60岁(范围46-87),链接国家数据库及病历复核分析治疗模式、复发和死亡。

主要发现

  • 9938例中2931例行全乳切除,7007例(70%)行保乳手术;中位随访64个月,697例(6.8%)出现进一步DCIS或浸润癌,保乳术后7.8%、全乳切除术后4.5%(p < 0.001)。
  • 保乳术后放疗4363/7007例(62.3%),与同侧复发DCIS或浸润癌绝对降低3.1%相关(未放疗7.2% vs 放疗4.1%,p < 0.001),与同侧浸润癌复发绝对降低1.9%相关(未放疗3.8% vs 放疗1.9%,p < 0.001),独立于切缘宽度或DCIS大小。
  • 保乳术后未放疗者中,径向切缘<2 mm与更多同侧乳腺复发相关(p < 0.001)。
  • 辅助内分泌治疗1208/9938例(12%),与任何同侧复发减少相关:保乳术后接受放疗者HR 0.57(95%CI 0.41-0.80),未接受放疗者HR 0.68(95%CI 0.51-0.91)。
  • 发生浸润癌复发者生存差于复发DCIS者(p < 0.001);321例(3.2%)死亡中仅46例归因于浸润性乳腺癌。

临床怎么用

  • 筛查检出DCIS保乳术后可考虑放疗以降低同侧复发风险,尤其切缘<2 mm且未放疗者复发风险更高。
  • 辅助内分泌治疗可考虑用于降低保乳术后同侧复发风险,无论是否接受放疗。
  • 治疗决策需权衡复发降低与5年内乳腺癌死亡率未见改善,并关注浸润性复发对生存的不良影响。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of screen-detected ductal carcinoma in situ (DCIS) remains controversial. METHODS: A prospective cohort of patients with DCIS diagnosed through the UK National Health Service Breast Screening Programme (1st April 2003 to 31st March 2012) was linked to national databases and case note review to analyse patterns of care, recurrence and mortality. RESULTS: Screen-detected DCIS in 9938 women, with mean age of 60 years (range 46-87), was treated by mastectomy (2931) or breast conserving surgery (BCS) (7007; 70%). At 64 months median follow-up, 697 (6.8%) had further DCIS or invasive breast cancer after BCS (7.8%) or mastectomy (4.5%) (p < 0.001). Breast radiotherapy (RT) after BCS (4363/7007; 62.3%) was associated with a 3.1% absolute reduction in ipsilateral recurrent DCIS or invasive breast cancer (no RT: 7.2% versus RT: 4.1% [p < 0.001]) and a 1.9% absolute reduction for ipsilateral invasive breast recurrence (no RT: 3.8% versus RT: 1.9% [p < 0.001]), independent of the excision margin width or size of DCIS. Women without RT after BCS had more ipsilateral breast recurrences (p < 0.001) when the radial excision margin was <2 mm. Adjuvant endocrine therapy (1208/9938; 12%) was associated with a reduction in any ipsilateral recurrence, whether RT was received (hazard ratio [HR] 0.57; 95% confidence interval [CI] 0.41-0.80) or not (HR 0.68; 95% CI 0.51-0.91) after BCS. Women who developed invasive breast recurrence had a worse survival than those with recurrent DCIS (p < 0.001). Among 321 (3.2%) who died, only 46 deaths were attributed to invasive breast cancer. CONCLUSION: Recurrent DCIS or invasive cancer is uncommon after screen-detected DCIS. Both RT and endocrine therapy were associated with a reduction in further events but not with breast cancer mortality within 5 years of diagnosis. Further research to identify biomarkers of recurrence risk, particularly as invasive disease, is indicated.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Thompson AM, Clements K, Cheung S, et al. Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. Eur J Cancer. 2018. PMID: 30092498. doi:10.1016/j.ejca.2018.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。